GlassScriptPhysician profile
Jimmy Gilbert
NPI 1629040936
$1,197.56
in general payments reported to CMS, 2019-2025
20 companies · $17.82 in 2025
The $17.82 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $104 · 2021: $164 · 2022: $281 · 2023: $113 · 2024: $315 · 2025: $17.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $446.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $365.23 | 2023-2024 | Inspire |
| Glaxosmithkline, LLC. | $170.58 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $156.54 | 2019-2024 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.65 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $55.22 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.18 | 2019-2022 | |
| Grifols USA, LLC | $49.01 | 2021-2022 | |
| Shire North American Group INC | $32.94 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $28.42 | 2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $22.61 | 2022 | |
| Genzyme Corporation | $21.59 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.71 | 2021 | |
| Foundation Medicine, INC. | $18.95 | 2021 | |
| Genentech USA, INC. | $18.40 | 2022 | |
| Mylan Specialty L.P. | $18.34 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $17.82 | 2025 | |
| Philips North America LLC | $16.29 | 2019 | |
| Csl Behring | $12.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.84 | 2021 | |
| Gilead Sciences, INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jimmy Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.